Fact checked by Nick Blackmer More people with type 1 diabetes are using GLP-1s like Ozempic and Zepbound, a new study ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Use of cutting-edge weight-loss drugs like Ozempic and Zepbound has increased dramatically among people with type 1 diabetes, raising safety concerns among experts, a new study says.

MG Motor Australia has announced that it will be launching its new IM electric luxury arm locally after making a public debut at next month’s Melbourne Motor Show, headed by the IM5 mid-size sedan and ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

Novo Nordisk and the Chinese group’s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, ...

According to Monday’s news release, the candidate, OPK-88006, is set to be the first oral GLP-1/glucagon agonist to start human studies. Under the terms of the agreement, OPKO and Entera will split ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.